Anna E. Pula

Lodz, LD, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Journal: Leukemia & lymphoma

Published: August 10, 2026

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Carfilzomib, lenalidomide, and dexamethasone compared with lenalidomide treatment after autologous haematopoietic stem-cell transplantation in patients with multiple myeloma (ATLAS): primary analysis of a randomised, open-label, phase 3 trial.

Journal: The Lancet. Haematology

Published: November 21, 2025

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

The Development of Novel Therapies for Chronic Lymphocytic Leukaemia in the Era of Targeted Drugs.

Journal: Journal of clinical medicine

Published: October 27, 2025

Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Correction for: Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Journal: Contemporary oncology (Poznan, Poland)

Published: October 16, 2025

Considerations for the treatment of older adults with chronic lymphocytic leukemia.

Considerations for the treatment of older adults with chronic lymphocytic leukemia.

Journal: Expert review of clinical pharmacology

Published: September 24, 2025

Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?

Indicators of an increased risk of therapy-related myeloid neoplasms in lymphoma patients: how can we best evaluate severe impairment of bone marrow function?

Journal: Expert review of hematology

Published: August 08, 2025

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant.

Journal: HemaSphere

Published: March 21, 2025

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma.

Journal: Blood neoplasia

Published: March 17, 2025

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma.

Journal: Leukemia

Published: March 07, 2025

Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Accelerated chronic lymphocytic leukemia - characteristics and retrospective analysis of the Polish Adult Leukemia Study Group.

Journal: Contemporary oncology (Poznan, Poland)

Published: January 13, 2025

Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.

Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.

Journal: Blood cancer journal

Published: December 28, 2024

Serum KL-6 and SP-D: Markers of Lung Function in Autoimmune-Related Interstitial Lung Diseases.

Serum KL-6 and SP-D: Markers of Lung Function in Autoimmune-Related Interstitial Lung Diseases.

Journal: International journal of molecular sciences

Published: November 29, 2024

Showing 1-12 of 22

Last Updated: 09/26/2026